<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Neutropenic pediatric patients with <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> and malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were treated with recombinant granulocyte-macrophage colony stimulating factor (rh-GM-CSF) </plain></SENT>
<SENT sid="1" pm="."><plain>Eleven patients, including seven lympho-reticular <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, two Ewing's <z:hpo ids='HP_0100242'>sarcoma</z:hpo> and one patient in each group with the diagnosis of nasopharyngeal <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo>, <z:e sem="disease" ids="C1261473" disease_type="Neoplastic Process" abbrv="">malignant mesenchymal tumor</z:e>, entered the study </plain></SENT>
<SENT sid="2" pm="."><plain>Six were females and five were males, the mean age was 10.4 yr, the range was 4 to 21 years </plain></SENT>
<SENT sid="3" pm="."><plain>rh-GM-CSF was given at the dose of 5 micrograms/kg s.c. daily, starting either on the day following the last day of cytotoxic chemotherapy or when ANC &lt; 1000/ml was determined </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received rh-GM-CSF for a total of seven days </plain></SENT>
<SENT sid="5" pm="."><plain>Hematopoietic recovery occurred in <z:hpo ids='HP_0000001'>all</z:hpo> children except one </plain></SENT>
<SENT sid="6" pm="."><plain>The response to rh-GM-CSF was achieved in a mean time of 7.4 days </plain></SENT>
<SENT sid="7" pm="."><plain>Tolerance to rh-GM-CSF treatment was good </plain></SENT>
<SENT sid="8" pm="."><plain>Adverse events were documented as <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo>, <z:hpo ids='HP_0002013'>vomiting</z:hpo>, <z:mp ids='MP_0002899'>fatigue</z:mp>, chills and <z:e sem="disease" ids="C0033774" disease_type="Disease or Syndrome" abbrv="">itching</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Sagittal sinus <z:mp ids='MP_0005048'>thrombosis</z:mp> developed in one patient 5 days following the completion of chemotherapy and rh-GM-CSF cycle </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, rh-GM-CSF can be applied during the intensive chemotherapy schedules of <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">pediatric cancer</z:e> patients </plain></SENT>
</text></document>